Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Using computational tools and virtual screening, researchers at the Center for Redox Processes in Biomedicine (Redoxoma) have ...

Mar. 12, 2025 — A lung function test used to help diagnose asthma works better in the morning, becoming less reliable throughout the day, researchers have found. Using real world data from 1,600 ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy ...

In a recent, cross-institutional study partially funded by the National Institutes of Health, researchers report that healthy human airways are at higher risk for dehydration and inflammation when ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...